A Single-Arm Phase II Clinical Study of Sacituzumab Tirumotecan Combined With a PD-1 Inhibitor as Second-Line Therapy for Advanced Esophageal Squamous Cell Carcinoma After Failure of or Progression on Immunotherapy
This study is a single-center, single-arm, prospective clinical study enrolling a total of 30 patients with advanced metastatic esophageal squamous cell carcinoma who have failed or progressed after prior first-line immunotherapy or immunotherapy combined with chemotherapy.
After signing the informed consent form, subjects will undergo screening assessment within 28 days prior to the first dose to determine whether they meet the study requirements. Subjects who meet the study inclusion and exclusion criteria will receive sacituzumab tirumotecan and a PD-1 inhibitor.
Patients will receive sacituzumab tirumotecan (4 mg/kg IV d1 Q2W) in combination with a PD-1 inhibitor for 6 cycles, followed by maintenance therapy with a PD-1 inhibitor-based regimen.
until investigator-confirmed radiological disease progression, unacceptable toxicity, the subject's request to discontinue treatment, or other protocol-specified criteria for treatment discontinuation, whichever occurs first; Eligible subjects will undergo regular tumor assessments based on RECIST 1.1. Within 48 weeks (within the first year) after dosing, imaging examinations for tumor assessment will be performed every 6 weeks (±7 days); after 48 weeks, tumor assessment will be performed every 12 weeks (±7 days), until radiological disease progression, initiation of new anti-tumor therapy, withdrawal of informed consent by the subject, loss to follow-up, death, or termination of the study by the sponsor, whichever occurs first. Imaging examinations will be performed as scheduled regardless of dose delay or adjustment. After a patient first achieves complete response (CR) or partial response (PR), the observed response must be confirmed at least 4 weeks (28 days) later.
For subjects who discontinue treatment for reasons other than radiological disease progression, death or loss to follow-up, imaging examinations should be repeated at the EOT visit if more than 4 weeks have elapsed since the previous imaging examination; subsequent imaging examinations should be performed as scheduled as far as possible until radiological disease progression, initiation of new anti-tumor therapy, withdrawal of informed consent by the subject, loss to follow-up, death, or termination of the study by the sponsor, whichever occurs first.
After the end of treatment, regardless of whether a new anti-tumor therapy is initiated, safety follow-up must be completed for the subject, and survival follow-up visits will be continued by telephone every 3 months (±14 days) after the last dose of study treatment to obtain survival information and information on new anti-tumor therapy, until the subject decides to withdraw from the study, loss to follow-up, death, or the end of the study, whichever occurs first.
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Tipo de estudo
Tipo de estudo
Inscrição (Estimado)
Inscrição
Estágio
Estágio
- Fase 2
Contactos e Locais
Contato de estudo
Contato de estudo
- Nome: Rui Liu
- Número de telefone: 022 23340123
- E-mail: liurui9003@163.com
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Histopathologically confirmed unresectable advanced metastatic esophageal squamous cell carcinoma;
- Age 18-75 years, male or female;
- At least one measurable lesion according to the Response Evaluation Criteria in Solid Tumors (iRECIST 1.1); measurable lesions should not have received prior local therapy such as radiotherapy;
- Failure (disease progression or unacceptable toxicity) of prior first-line immunotherapy or immunotherapy combined with chemotherapy; patients who relapse within 6 months after the end of adjuvant/neoadjuvant therapy, if the treatment regimen was immunotherapy or immunotherapy combined with chemotherapy, will be regarded as having failed first-line treatment and may be enrolled;
- Expected survival of ≥12 weeks;
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 7 days before dosing;
- Radiologically confirmed disease progression during or after the most recent treatment for advanced or metastatic disease;
- Adequate organ and bone marrow function (no blood transfusion, recombinant human thrombopoietin or colony-stimulating factor within 2 weeks prior to the first dose)
- Female subjects of childbearing potential and male subjects whose partners are of childbearing potential must agree to use effective medical contraception from the signing of the informed consent form until 6 months after the last dose; 10) Subjects voluntarily participate in this study, sign the informed consent form, and are able to comply with the visits and related procedures specified in the protocol.
Exclusion Criteria:
- Subjects with known meningeal metastasis, brainstem metastasis, spinal metastasis and/or compression, or active or untreated central nervous system (CNS) metastasis. Subjects with brain metastasis who have received prior local therapy may be enrolled if they are clinically stable for at least 4 weeks before dosing and do not require glucocorticoids or anticonvulsants for at least 14 days;
- Patients who experienced disease progression within 3 months during prior first-line treatment;
- Prior receipt of TROP2-targeted therapy; prior receipt of any topoisomerase I inhibitor drug or chemotherapy;
- Presence of persistent or active infection;
- Participation in other anti-tumor drug clinical trials within 4 weeks before screening;
- Presence of adverse events of CTCAE > Grade 1 before the first dose (excluding alopecia and endocrine toxicity);
- Presence of other uncured malignancies within 5 years (except cured basal cell carcinoma of the skin and carcinoma in situ of the cervix);
- Positive human immunodeficiency virus (HIV) test or a history of acquired immunodeficiency syndrome (AIDS); known active syphilis infection;
- Known hypersensitivity to the study drug or any of its components;
- History of (non-infectious) interstitial lung disease (ILD) or non-infectious pneumonitis requiring steroid treatment, current ILD or non-infectious pneumonitis, or suspected ILD or non-infectious pneumonitis that cannot be excluded by imaging examination at screening;
- Poorly controlled diabetes mellitus (fasting blood glucose ≥ 10 mmol/L on two consecutive measurements);
- Presence of clinically symptomatic pleural effusion, pericardial effusion or ascites requiring repeated drainage (> once per week);
- Documented severe dry eye syndrome, severe meibomian gland disease and/or blepharitis, or a history of corneal disease that prevents or delays corneal healing; Any condition that, in the investigator's judgment, interferes with the evaluation of the study drug, the safety of the subject or the interpretation of study results, or any other condition considered by the investigator to make the subject unsuitable for participation in this study.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Experimental: Sacituzumab tirumotecan combined with PD-1 inhibitor
Patients will receive sacituzumab tirumotecan (4 mg/kg IV d1 Q2W) in combination with a PD-1 inhibitor for 6 cycles, followed by maintenance therapy with a PD-1 inhibitor-based regimen. |
Patients will receive sacituzumab tirumotecan (4 mg/kg IV d1 Q2W) in combination with a PD-1 inhibitor for 6 cycles, followed by maintenance therapy with a PD-1 inhibitor-based regimen.
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
progression-free survival (PFS)
Prazo: 2years
|
To evaluate progression-free survival (PFS) with sacituzumab tirumotecan combined with a PD-1 inhibitor: the time from enrollment to radiologically confirmed disease progression (PD) (per iRECIST 1.1) or death from any cause without documented progression; |
2years
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
objective response rate (ORR)
Prazo: 1year
|
To evaluate the objective response rate (ORR) of sacituzumab tirumotecan combined with a PD-1 inhibitor: per iRECIST 1.1, the proportion of patients whose best overall response from enrollment to disease progression is CR or PR among all evaluable patients; |
1year
|
|
overall survival (OS)
Prazo: 3years
|
To evaluate overall survival (OS) with sacituzumab tirumotecan combined with a PD-1 inhibitor: the time from enrollment to death from any cause; |
3years
|
|
duration of response (DOR)
Prazo: 1year
|
To evaluate the duration of response (DOR) with sacituzumab tirumotecan combined with a PD-1 inhibitor: the time from the first assessment meeting CR or PR criteria to the observation of PD or death, whichever occurs first; calculated only for patients whose best overall response is CR or PR |
1year
|
|
adverse events (AEs)
Prazo: 2years
|
During this study and the follow-up period, the severity of adverse events will be graded and assessed according to NCI CTCAE (version 5.0). Safety evaluation indicators include: The incidence, severity and relationship to the study drug of all adverse events (AEs), treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs); The number and proportion of subjects with dose reduction and treatment discontinuation due to the above adverse events; Changes in vital signs, physical examination findings and laboratory results before, during and after study treatment. |
2years
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Neoplasias por local
- Neoplasias
- Neoplasias por Tipo Histológico
- Neoplasias gastrointestinais
- Neoplasias do Aparelho Digestivo
- Doenças do aparelho digestivo
- Doenças Gastrointestinais
- Neoplasias de Cabeça e Pescoço
- Neoplasias Glandulares e Epiteliais
- Doenças Esofágicas
- Carcinoma
- Neoplasias de Células Escamosas
- Carcinoma de Células Escamosas
- Neoplasias Esofágicas
- Carcinoma Espinocelular de Esôfago
- Agentes Antineoplásicos Imunológicos
- Agentes Antineoplásicos
- Mecanismos Moleculares de Ação Farmacológica
- Ações farmacológicas
- Ações e usos químicos
- Usos terapêuticos
- Inibidores de Ponto de Verificação Imunológica
Outros números de identificação do estudo
Outros números de identificação do estudo
- E20261246
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .